Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

777
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
777
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.3K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

339
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
339
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

552
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
552
Drug Therapy01:28

Drug Therapy

170
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
170
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

650
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
650

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The utility of a composite endpoint for tracking disease progression in Lewy body dementia.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Cerebrospinal fluid orexin testing in Australians with narcolepsy type 1.

Internal medicine journal·2026
Same author

Mirabegron and Intradetrusor Onabotulinumtoxina for Overactive Bladder in Parkinson's Disease: A Systematic Review and Meta-Analysis.

Neurourology and urodynamics·2026
Same author

Reduced serum interleukin-2 associates with higher motor severity and along with CD4 T cell alterations may be an early event in isolated REM Sleep Behaviour Disorder.

Brain, behavior, & immunity - health·2026
Same author

Cognitive resilience in ageing: determinants and interventions.

The Lancet. Neurology·2026
Same author

Health Care Outcomes Associated With Cognitive Super-Ageing.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2026

Related Experiment Video

Updated: Nov 30, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.2K

Treating hallucinations in Parkinson's disease.

Alice Powell1,2, Elie Matar1, Simon J G Lewis1

  • 1ForeFront Parkinson's Disease Research Clinic, Brain and Mind Centre, School of Medical Sciences, the University of Sydney, Camperdown, Australia.

Expert Review of Neurotherapeutics
|November 13, 2020
PubMed
Summary

Hallucinations in Parkinson's disease (PD) are common and impact quality of life. Management requires individualized, multifaceted approaches, including medication review and specific treatments like acetylcholinesterase inhibitors.

Keywords:
HallucinationsLewy body diseaseParkinson’s diseasepsychosistreatment

More Related Videos

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

75.0K
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.7K

Related Experiment Videos

Last Updated: Nov 30, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.2K
Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

75.0K
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.7K

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Hallucinations are a frequent and debilitating non-motor symptom in Parkinson's disease.
  • These symptoms significantly impair patient quality of life and complicate treatment strategies.

Purpose of the Study:

  • To review current evidence and expert opinion on managing hallucinations in Parkinson's disease.
  • To outline recommended therapeutic approaches for this challenging aspect of PD.

Main Methods:

  • Systematic review of existing literature on Parkinson's disease hallucinations.
  • Synthesis of expert recommendations for clinical management.

Main Results:

  • Individualized and multifaceted treatment strategies are essential.
  • Key interventions include screening, patient education, medication review, and trigger avoidance.
  • Acetylcholinesterase inhibitors are first-line for visual hallucinations; atypical antipsychotics may be used cautiously for severe cases.

Conclusions:

  • Current treatments for Parkinson's disease hallucinations offer limited efficacy.
  • Further research is critically needed to develop more effective therapies.
  • A comprehensive approach combining pharmacological and non-pharmacological strategies is recommended.